Use of SGLT2-inhibitors for type 2 diabetes in acute inpatient care
Published: February 2023. Next review: 2028.
This clinical practice guide outlines the safe use of sodium glucose co-transporter2-inhibitor (SGLT2-i) medicines for people with type 2 diabetes receiving acute inpatient care in NSW hospitals.
It aims to reduce the risk of SGLT2-i-induced diabetic ketoacidosis and improve the early recognition and diagnosis of diabetic ketoacidosis that may be euglycaemic.
It covers:
- when to withhold SGLT2-i medicines
- restarting SGLT2-i medicines after they have been withheld
- use of SGLT2-i medicines in the periprocedural period
- starting SGLT2-i medicines in hospital (in circumstances where this is considered clinically important).
SGLT2-i medicines are not approved for use in type 1 diabetes.
Diabetes SGLT2 inhibitors - evidence check
Published: March 2023.
SGLT2 inhibitors are one of the newest classes of drugs that are used for blood glucose control in patients with type 2 diabetes. The rapid evidence check informed the guidance provided in the clinical practice guide.
Focusing on people with diabetes in an inpatient setting, the evidence check explored the:
- safety of the use of sodium-glucose co-transporter-2 (SGLT2) inhibitors
- existing recommendations regarding the use of SGLT2 inhibitors.